Princess Maxima Center For Pediatric Oncology

This study is testing a new combination of two chemotherapy drugs, Vyxeos® and clofarabine, for children and young adults whose acute myeloid leukemia (AML) has come back or hasn't responded to standard treatments. The main goal is to find the safest and most effective dose of th…

This study is testing a drug called brigatinib in children and young adults (ages 1 to under 26) with specific cancers that have a genetic change called ALK-positive. The cancers include anaplastic large cell lymphoma (ALCL), inflammatory myofibroblastic tumors (IMT), and other s…

This trial is testing a new combination of targeted drugs (ruxolitinib and venetoclax) with standard chemotherapy for children and young adults whose leukemia or lymphoma has come back or not responded to prior treatment. It aims to see if this approach is safe and effective for …

This trial is testing a new combination of targeted drugs for children and young adults whose acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) has come back or not responded to standard treatments. It aims to see if matching drugs to specific genetic changes in …

This trial is testing a new combination of drugs for children and young adults whose leukemia or lymphoma has come back or hasn't responded to standard treatments. It specifically targets cancers with certain genetic changes. The goal is to see if adding a targeted drug called tr…

This international study is testing a drug called blinatumomab for infants under one year old who have a specific, hard-to-treat type of leukemia. The goal is to see if adding this drug to standard chemotherapy can better control the cancer, prevent it from coming back, and impro…

This study is creating a European expert panel to review detailed cancer information from children and young adults whose leukemia or lymphoma has returned or not responded to treatment. The panel's goal is to provide personalized advice to the child's doctor, recommending the be…